Medincell Posts €24.3M Revenue as UZEDY Royalties Grow, Expenses Rise
Event summary
- Medincell reported FY 2025-26 revenue of €24.3M, including €9.3M from UZEDY royalties.
- Operating loss widened to €20.8M due to a 17% YoY increase in operating expenses to €45.0M.
- Cash position strengthened to €84.8M after a €48.2M fundraising in March 2026.
- Teva's planned commercial launch of Olanzapine LAI expected later in 2026.
The big picture
Medincell's FY 2025-26 results reflect its strategic shift toward commercial-stage operations, with UZEDY royalties driving recurring revenue. The company's increased investment in its pipeline aligns with broader industry trends toward long-acting injectables, which aim to improve patient adherence and treatment outcomes. The upcoming launch of Olanzapine LAI with Teva could further validate Medincell's technology platform, but the company must demonstrate it can convert these opportunities into sustainable profitability.
What we're watching
- Revenue Diversification
- How Medincell will balance milestone revenues with recurring royalties as UZEDY and other products mature.
- Execution Risk
- Whether the company can sustain its growth trajectory while managing increased operating expenses.
- Pipeline Progress
- The pace at which Medincell advances its pipeline of long-acting injectable treatments.
Related topics